Home / Stocks / Vivo Bio Tech Ltd.
VIVOBIOT

Vivo Bio Tech Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹14.32

Change

-1.08 (-7.01%)

Open

₹15.94

Prev. Close

₹15.4

Day High

₹15.94

Day Low

₹14.0

Volume Analysis

Traded

24,835

Delivered

19,904

Delivery %

80.14%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (35.62%)

Weaknesses (3)

  • •Low return on equity (-2.24%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (31/100)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹17.44 ₹16.69 ₹15.5 ₹14.75 ₹13.56 ₹12.81 ₹11.62
Fibonacci ₹16.69 ₹15.95 ₹15.49 ₹14.75 ₹14.01 ₹13.55 ₹12.81
Camarilla ₹14.85 ₹14.68 ₹14.5 ₹14.75 ₹14.14 ₹13.96 ₹13.79

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-12.79%

1 Month

+2.95%

3 Months

-23.55%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-2.5%

Net margin -4.43% × asset turnover 0.27x × equity multiplier 2.09x

Company Overview

Sector

Healthcare

Market Cap

₹35 Cr

ROE

-2.24%

Book Value

₹42.6

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Vivo Bio Tech Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 31/100. The strongest factor is Financial Strength (66/100), while Growth (3/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (35.62%); low return on equity (-2.24%); promoter holding is falling.

TopFund Score — Fundamentals Quality

31/100 — Weak

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

66

Growth

3

Valuation

18

Cash Flow

33

Corporate Governance

14

Momentum

17

Business Quality

45

Risk & Volatility

19

Liquidity

50

From Screener.in

  • +Stock is trading at 0.37 times its book value
  • −Company has low interest coverage ratio.
  • −Promoter holding has decreased over last quarter: -8.11%
  • −The company has delivered a poor sales growth of 0.59% over past five years.
  • −Promoter holding is low: 22.5%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication of financial results for the second quarter & half year ended September 30, 2026.

Reported nil re-lodgement transfer requests for physical shares in October 2026.

Board approved unaudited standalone and consolidated Q2 FY2026 results on November 11, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 9 13 12 10 12 12 12 13 13 14 14 14 17
Expenses + 4 6 6 6 6 7 7 7 8 8 10 9 11
Operating Profit 5 6 5 4 6 6 5 5 5 5 4 5 6
OPM % 52.48% 49.57% 45.66% 43.04% 46.43% 45.37% 40.85% 43.8% 41.34% 40.64% 31.34% 35.36% 35.43%
Other Income + 0 0 0 0 5 0 0 0 0 0 0 0 2
Interest 2 2 2 2 2 2 2 2 1 1 1 1 2
Depreciation 2 2 2 2 2 2 2 3 3 3 3 4 4
Profit before tax 0 2 1 0 6 1 1 1 2 2 0 0 2
Tax % 29.79% 31.05% 48.95% 27.27% 10.73% 43.84% 14.52% 9.46% 42.38% 20.38% 2,164.0% 44.12% 41.18%
Net Profit + 0 1 1 0 5 1 1 1 1 1 -5 0 1
EPS in Rs 0 1 1 0 4 1 1 1 0 1 -2 0 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -27 -5 -20 -13 30 -5 5 23 9 11 16 14 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 18 29 34 47 56 55 52 51 52 45 47 53 59
Expenses + 15 25 27 36 46 43 34 35 30 24 26 32 38
Operating Profit 3 4 8 11 10 12 18 16 22 21 21 22 21
OPM % 15.74% 12.98% 22.33% 23.17% 17.03% 22.53% 34.38% 31.31% 41.82% 46.78% 44.05% 40.33% 35.62%
Other Income + 1 1 0 0 0 0 0 0 0 0 5 0 2
Interest 1 0 1 2 3 3 4 4 8 8 8 6 6
Depreciation 3 3 4 5 5 5 6 7 9 9 9 11 13
Profit before tax 0 1 3 4 2 4 9 4 5 4 9 5 4
Tax % -142.11% -16.67% 11.66% 21.95% -23.08% -4.47% 34.11% 50.78% 42.64% 37.93% 17.18% 135.55% —
Net Profit + 0 1 3 3 2 4 6 2 3 3 7 -2 -3
EPS in Rs 0 1 3 3 2 3 4 2 2 2 4 -1 -1
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 10 61 19 38 19 -1 -6 -1 2 -13 3 14 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 0 1 3 9 15 20 29 33 37 40 61 71 72
Borrowings + 6 17 27 25 22 24 31 67 62 73 54 67 83
Other Liabilities + 27 19 11 15 6 6 6 8 9 10 11 18 20
Total Liabilities 41 46 51 60 55 64 80 122 123 137 143 178 197
Fixed Assets + 20 24 29 28 30 35 52 95 89 80 88 123 122
CWIP 0 0 3 4 0 0 0 1 2 9 13 5 16
Investments 0 0 0 0 0 0 0 0 0 0 0 22 24
Other Assets + 22 22 20 28 25 29 27 26 32 48 42 29 35
Total Assets 41 46 51 60 55 64 80 122 123 137 143 178 197
Equity Capital 9 9 9 10 12 13 13 14 15 15 17 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 2 9 -6 11 -1 9 14 17 15 16 12 35
Cash from Investing Activity + -2 -7 -12 -5 -4 -10 -23 -51 -4 -8 -16 -59
Cash from Financing Activity + -1 0 7 -3 1 2 9 35 -11 -8 4 25
Net Cash Flow -1 1 -11 3 -4 0 0 1 0 0 0 0
Free Cash Flow 0 2 -18 6 -4 -2 -9 -34 11 8 -4 -3
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 81 234 -70 110 -13 68 96 118 77 80 65 166

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 42.08% → 22.51%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 57.92% 57.92% 57.92% 57.91% 61.12% 59.16% 60.94% 64.84% 64.84% 64.58% 69.39% 77.5%
Promoters 42.08% 42.08% 42.08% 42.08% 38.89% 40.85% 39.07% 35.17% 35.17% 35.43% 30.62% 22.51%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Vivo Bio Tech Ltd. (this stock) 35 — 0.37 -2.24%
Medi Caps Ltd. 33 — 0.27 -9.21%
Gkb Ophthalmics Ltd. 31 11.2 0.56 3.28%
Vivimed Labs Limited 43 — -0.2 —
Mangalam Drug & Chem Ltd 45 — 0.51 -35.3%
Ortin Global Limited 11 — — —
Sunil Healthcare Ltd. 78 26.6 1.03 6.01%

Which Mutual Funds Hold Vivo Bio Tech Ltd.?

Frequently Asked Questions about Vivo Bio Tech Ltd.

Community Sentiment

What are other investors saying about Vivo Bio Tech Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.